GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTL) » Definitions » Shiller PE Ratio

ARTL (Artelo Biosciences) Shiller PE Ratio : (As of Apr. 12, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Artelo Biosciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Artelo Biosciences Shiller PE Ratio Historical Data

The historical data trend for Artelo Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences Shiller PE Ratio Chart

Artelo Biosciences Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Artelo Biosciences Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Artelo Biosciences's Shiller PE Ratio

For the Biotechnology subindustry, Artelo Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artelo Biosciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Artelo Biosciences's Shiller PE Ratio falls into.


;
;

Artelo Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Artelo Biosciences's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Artelo Biosciences's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-1.17/133.1571*133.1571
=-1.170

Current CPI (Dec. 2024) = 133.1571.

Artelo Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201502 -0.123 99.032 -0.165
201505 -0.048 100.333 -0.064
201508 -0.072 100.548 -0.095
201511 -0.239 100.135 -0.318
201602 -0.080 100.040 -0.106
201605 -0.079 101.355 -0.104
201608 -0.068 101.617 -0.089
201611 -0.149 101.829 -0.195
201702 -0.204 102.779 -0.264
201705 -1.200 103.256 -1.548
201708 -2.400 103.587 -3.085
201711 -2.400 104.072 -3.071
201802 -8.400 105.052 -10.647
201805 -5.400 106.148 -6.774
201808 -10.950 106.383 -13.706
201811 -4.800 106.338 -6.011
201902 -6.000 106.649 -7.491
201905 -2.550 108.048 -3.143
201908 -4.500 108.245 -5.536
201911 -5.850 108.519 -7.178
202002 -6.000 109.139 -7.320
202005 -4.050 108.175 -4.985
202008 -3.000 109.662 -3.643
202011 -2.100 109.793 -2.547
202102 -1.650 110.968 -1.980
202105 -1.500 113.576 -1.759
202108 -1.020 115.421 -1.177
202111 -1.200 117.269 -1.363
202203 -0.700 121.301 -0.768
202206 -0.870 125.017 -0.927
202209 -0.820 125.227 -0.872
202212 -1.180 125.222 -1.255
202303 -0.760 127.348 -0.795
202306 -0.560 128.729 -0.579
202309 -0.830 129.860 -0.851
202312 -0.990 129.419 -1.019
202403 -0.780 131.776 -0.788
202406 -0.750 132.554 -0.753
202409 -0.350 133.029 -0.350
202412 -1.170 133.157 -1.170

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Artelo Biosciences  (NAS:ARTL) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Artelo Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Artelo Biosciences Business Description

Traded in Other Exchanges
N/A
Address
505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Executives
Gregory D. Gorgas director, officer: See Remarks 888 PROSPECT, SUITE 210, LA JOLLA CA 92037
Tamara A Seymour director C/O SIGNAL GENETICS, INC., 5740 FLEET STREET, CARLSBAD CA 92008
Gregory Reyes director 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Matsui Connie director 3030 CALLAN RD, SAN DIEGO CA 92121
John W Beck director C/O RITTER PHARMACEUTICALS, INC., 1880 CENTURY PARK EAST, SUITE 1000, LOS ANGELES CA 90067
Robert Martin Emanuele director
David J Moss 10 percent owner C/O PEGASI ENERGY RESOURCES CORPORATION, 218 N. BROADWAY, SUITE 204, TYLER TX 75702
Georgia Erbez director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Steven Kelly director C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022
Douglas Blayney director C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037
Peter Michael O'brien 10 percent owner C/O ARTELO BIOSCIENCES, INC., 888 PROSPECT ST, SUITE 210, LA JOLLA CA 92037